KF
EPZM

Krilogy Financial’s Epizyme, Inc EPZM Stock Holding History

Krilogy Financial’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-300
Closed -$3K – 739
2018
Q3 		$3K Buy
+300
New +$3.42K ﹤0.01% 699
2018
Q2 		– Sell
-300
Closed -$5K – 678
2018
Q1 		$5K Buy
+300
New +$5.07K ﹤0.01% 612

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Krilogy Financial's EPZM Position: Q4 2018 in Review

Krilogy Financial sold out of Epizyme, Inc (EPZM) in Q4 2018, closing a stake of 300 shares — an estimated $3K sold.

Krilogy Financial first reported a position in EPZM in Q1 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 105 funds tracked by Wall St. Rank hold EPZM as of Q4 2018.

  • Krilogy Financial reported no remaining Epizyme, Inc position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 300 Epizyme, Inc shares in Q4 2018, an estimated $3K.
  • Krilogy Financial first reported a position in Epizyme, Inc in Q1 2018 and held it in 2 quarters.
  • Krilogy Financial's Epizyme, Inc position peaked at $5K in Q1 2018.
  • 105 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.